公司資料
Legend Biotech Corporation 股價、新聞與催化劑
- 股票代碼:
- LEGN
- 交易所:
- NASDAQ
- 產業:
- CAR-T Therapy, TCR-T Therapy, Antibody Drugs, ADCs, Biopharma
- 所在地:
- China with major global operations and listed in the U
股票表現
20.65 USD (+1.37%)
收盤價
最後更新: 2026年8月17日
6.74B USD
市值
股價為何變動
As of Aug 17, 2026, LEGN closed up 1.37% at $20.65. No new same-company headline was identified in the current news window.
公司概覽
Global Cell Therapy Company
Legend Biotech develops and commercializes cell therapies for cancer and other serious diseases.
CARVYKTI
CARVYKTI, or ciltacabtagene autoleucel, is a one-time BCMA-directed CAR T-cell therapy for multiple myeloma developed and commercialized with Johnson & Johnson.
Global Manufacturing and Access
Legend supports CARVYKTI across 18 markets through expanding manufacturing capacity, treatment-center certification, and partner-led commercialization.
CARVYKTI Clinical Expansion
The cilta-cel franchise is being developed across earlier lines of multiple myeloma treatment to broaden access beyond heavily pretreated disease.
Earlier Cell Therapy Pipeline
The company is advancing additional cell therapies beyond BCMA, including programs for hematologic malignancies and solid tumors.
未來催化劑
- Legend Biotech’s catalysts are Carvykti sales growth, label-expansion opportunities, and further commercial execution in multiple myeloma. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。